Natco Pharma launches drug for gastric & colorectal cancer

November 19, 2021 | Friday | News

The drug is being offered at an affordable price

Image Credit: Shutterstock

Image Credit: Shutterstock

Hyderabad-based Natco Pharma has launched a novel fixed-dose combination of Trifluridine + Tipiracil for the first time in India under the brand name Tipanat as a pack of 20 tablets in a bottle.

 

Tipanat is a novel antineoplastic nucleoside analogue indicated for the treatment of advanced colorectal and gastric cancer.

 

In India, approximately 1,25,000 new cases of the above-mentioned cancers are reported every year.

 

Tipanat is of high importance in not only extending survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need. NATCO has offered Tipanat at an affordable price.

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

Forgot your password?

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy